Analysis of IMP3 expression in prostate adenocarcinomas;Prostat adenokarsinomlarında IMP-3 ekspresyonunun araştırılması

Turk Patoloji Dergisi/Turkish Journal of Pathology

Volumn 28, Issue 2, 2012, Pages 128-133

  Tosun Yildirim, Hülya ^a   Şen Türk, Nilay ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Adenocarcinoma; Insulin like growth factor II; Pathogenesis; Prostate

Indexed keywords

INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; RNA BINDING PROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 84862640290     PISSN: 10185615     EISSN: 13095730     Source Type: Journal    
DOI: 10.5146/tjpath.2012.01111     Document Type: Article

References (23)

1. Bostwick DG, Meiers I: Neoplasms of the Prostate. In Bostwick DG, Cheng L. (Eds): Urologic Surgical Pathology. 2nd ed., Missouri, Mosby-Elsevier, 2008, 444-578
2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, IARC Pres, 2004, 160-215
3. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G, Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88:95-99
4. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstädter F, Burger M, Moch H, Kristiansen G: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 2010, 10:341
5. Li L, Xu H, Spaulding BO, Cheng L, Simon R, Yao JL, di Sant'Agnese PA, Bourne PA, Huang J: Expression of RNAbinding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Human Pathol 2008, 39:1205-1211
6. Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008, 14:1701-1706
7. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL: Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-564
8. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED: Oncofetal Protein IMP3: A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. American Cancer Society 2008, 112: 2676-2682
9. Özdemir NO, Türk NŞ, Düzcan E: IMP-3 expression in urothelial carcinomas of the urinary bladder. Türk Patoloji Dergisi 2011, 27:31-37
10. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA: How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006, 175:1337-1340
11. Samaratunga H, Epstein JI: What is the molecular pathology of low-risk prostate cancer? World J Ural 2008, 26:431-436
12. Lee JT, Lee S, Yun CJ, Jeon BJ, Kim JM, Ha HK, Lee W, Chung MK: Prediction of perineural invasion and its prognostic value in patients with prostate cancer. Korean J Urol 2010, 51:745-751
13. Nandeesha H: Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol 2009, 41:267-272
14. Gennigens C, Menetrier-Caux C, Droz JP: Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006, 58:124-145
15. Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P, Moore GE: Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russel syndrome. J Med Genet 2002, 39:575-581
16. Liao B, Hu Y, Herrick DJ, Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005, 280:18517-18524
17. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC: RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008, 48:1118-1127
18. Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probsthensch N, Jochum W, Kristiansen G: IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas Hum Pathol 2009, 40:1377-1383
19. Yu L, Xu H, Wasco MJ, Bourne PA, Ma L: IMP-3 expression in melanocytic lesions. J Cutan Pathol 2010, 37:316-322
20. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005, 29:188-195
21. Lu D, Vohra P, Chu PG, Woda B, Rock K, Jiang Z: An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia Am J Surg Pathol 2009, 33:521-525
22. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinomas. Br J Surg 2009, 96:66-73
23. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112:1471-1479